v3.26.3
Segments (Tables)
 9 Months Ended
Sep. 30, 2026
Single Reporting Segment  
Segment Reporting Information [Line Items]  
Schedule of segment revenue and expenses to consolidated net loss

The following table reconciles segment revenue and expenses to consolidated net loss for the three and nine months ended September 30, 2026 and 2025 (in thousands):

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Direct research and development expenses by program1,2:

 

 

 

 

 

 

 

 

 

 

 

 

Avexitide

 

$

10,661

 

 

$

4,886

 

 

$

30,009

 

 

$

17,417

 

AMX0035 - PSP

 

 

(425

)

 

 

2,995

 

 

 

260

 

 

 

14,704

 

Other programs3

 

 

7,373

 

 

 

4,033

 

 

 

19,983

 

 

 

12,564

 

Personnel-related research and development4

 

 

10,741

 

 

 

7,941

 

 

 

29,477

 

 

 

24,506

 

Selling, general and administrative

 

 

21,308

 

 

 

16,172

 

 

 

59,400

 

 

 

47,495

 

Interest income

 

 

(4,183

)

 

 

(1,821

)

 

 

(9,075

)

 

 

(6,012

)

Other segment items5

 

 

14

 

 

 

180

 

 

 

142

 

 

 

1,062

 

Net loss

 

$

(45,489

)

 

$

(34,386

)

 

$

(130,196

)

 

$

(111,736

)

1. The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM. As the Company has one reportable segment, there were no intersegment eliminations for the three and nine months ended September 30, 2026 and 2025.

2. Depreciation and amortization expense of less than 0.1 million and $0.2 million during the three and nine months ended September 30, 2026, respectively, and $0.1 million and $0.4 million during the three and nine months ended September 30, 2025, respectively, are allocated across the significant expense captions.

3. Other programs includes milestone payments totaling $4.0 million made to Gubra following the selection and handover of AMX0318 as a development candidate for PBH and other rare diseases during the nine months ended September 30, 2026.

4. The Company does not allocate personnel and other similar costs to specific programs because these costs are deployed across multiple programs.

5. Other segment items primarily consists of net realized and unrealized losses on foreign exchange transactions.